ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

VRP Verona Pharma Plc

55.00
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma Plc LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 55.00 45.00 65.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Verona Pharma Share Discussion Threads

Showing 12976 to 12997 of 13325 messages
Chat Pages: Latest  521  520  519  518  517  516  515  514  513  512  511  510  Older
DateSubjectAuthorDiscuss
14/2/2020
07:59
All positive.


Results

The study took place between July 2017 and February 2018. Of 405 patients randomly assigned to medication, 375 (92.6%) completed the study. For peak FEV1 at Week 4, all four ensifentrine doses were superior to placebo (p ≤ 0.0001) with least squares mean differences of 146 (95% CI 75–216), 153 (83–222), 200 (131–270) and 139 (69–210) mL for ensifentrine 0.75, 1.5, 3 and 6 mg, respectively. Respiratory symptoms (assessed using the Evaluating Respiratory Symptoms questionnaire) were also significantly improved with all ensifentrine doses at Week 4. Adverse events were reported by 33.3, 44.4, 35.4 and 36.3% patients with ensifentrine 0.75, 1.5, 3 and 6 mg, respectively, and 39.2% with placebo.
Conclusions

In this four-week Phase IIb study, all four ensifentrine doses significantly improved bronchodilation and symptoms, with a dose-ranging effect from 0.75 to 3 mg twice daily, and all doses well tolerated. The study supports the continuing development of ensifentrine in COPD.

It's a long road but end in sight.

ewads
14/2/2020
07:39
Wake wake news looks promising!!
joeblogg2
12/2/2020
21:51
Above average volume of 400k
matt123d
11/2/2020
11:04
I've been buying a few the last few days - seems like there's a clear trend in the price.



But Shore, in a note, pointed out: “Both Dr Zaccardelli and Mr Hahn bring significant experience, financial, operational and commercial, to lead Verona through its next phase of late-stage development.

“Further with the senior management team based in the US we would anticipate a more active US capital markets strategy and see this as a positive.

ohisay
10/2/2020
22:18
I'm waiting on trials coming up in a few months, made roughly 50% profit selling half my shares the day this was published: hxxps://ukinvestormagazine.co.uk/verona-pharma-shares-surge-over-50-on-positive-ensifentrine-trial/
dylanshares
10/2/2020
19:08
The share price here never seems to make the running! It always waits and follows Verona movements on NASDAQ.
Even this morning our share price should have matched Friday’s close on NASDAQ, but no, we waited, to ensure NASDAQ held the Friday close. When it did, we moved up.

bbonsall
10/2/2020
15:49
Getting some volume through today, should be at least 65p
matt123d
10/2/2020
15:48
Am only down £5k this time round as was hoping to recover part of my previous losses seeing this go to £1 but instead it has halved :( Hopefully some deals being lined up!!!
joeblogg2
06/2/2020
17:16
Added a few here today for a bounce
matt123d
03/2/2020
14:17
Only 10 years...Directors have been milking us for years with promises that never materialised
pjm1162
03/2/2020
10:38
Buy when the Directors buy might be a good strategy from hereon in !
ohisay
03/2/2020
09:26
...wouldnt be suprized. Ive been in VRP about 10 years and its always been jam tommorow. If these new changes were so good why dont we see a rise in the share price instaed of the usuual down?
haff1
03/2/2020
09:03
Placing on its way I wonder after the Management change ?
ohisay
29/1/2020
08:51
Drip dripFun over here40's looming imo
pjm1162
22/1/2020
14:37
I spotted it months ago, and noticed Piers Morgan investing more, so I bought in when it was low. I sold half my stock just before the masses made it drop - partly due to article below, it was up 50% that day. hxxps://ukinvestormagazine.co.uk/verona-pharma-shares-surge-over-50-on-positive-ensifentrine-trial/

Holding the other half for the upcoming studies/financial quarter. I think it's massively undervalued right now.

dylanshares
22/1/2020
14:04
Such an unloved share. Volume is pitiful.
wageslave
21/1/2020
21:12
over 11% up in the US - should have a good run upwards tomorrow!
sandy12345
21/1/2020
16:07
agree 100% bbanker, will accumulate as funds become available.
joeblogg2
21/1/2020
15:46
It’s a long way back but perhaps the market is beginning to understand that success with the research will be hugely welcome by the sufferers and will generate more interest in this stock that has little coverage from the pundits. I am a long term holder.
bbanker
21/1/2020
08:49
some good reading there, on the way up!
sandy12345
19/1/2020
18:12
Consensus target price broker views seem to be around £3 per share FWIW.
ohisay
17/1/2020
18:01
Who told you?
bbonsall
Chat Pages: Latest  521  520  519  518  517  516  515  514  513  512  511  510  Older

Your Recent History

Delayed Upgrade Clock